Sichuan Kelun Pharmaceutical Co Ltd (002422) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sichuan Kelun Pharmaceutical Co Ltd (002422) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥537.31 Million ≈ $78.62 Million USD) by net assets (CN¥28.62 Billion ≈ $4.19 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check 002422 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Sichuan Kelun Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Sichuan Kelun Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Sichuan Kelun Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sichuan Kelun Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ORION CORP.B UNSP.ADR 1/2
F:OFK0
|
0.033x |
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
N/A |
|
SPIE SA
PA:SPIE
|
0.362x |
|
Builders FirstSource Inc
NYSE:BLDR
|
0.022x |
|
Bharti Hexacom Ltd
NSE:BHARTIHEXA
|
0.173x |
|
GETLINK ADR EO-40
F:TNU
|
N/A |
|
Yanzhou Coal Mining Company Limited
F:YZC
|
0.000x |
|
BlueFocus Communication Group
SHE:300058
|
0.064x |
Annual Cash Flow Conversion Efficiency for Sichuan Kelun Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Sichuan Kelun Pharmaceutical Co Ltd (002422) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥29.29 Billion ≈ $4.29 Billion |
CN¥2.64 Billion ≈ $386.62 Million |
0.090x | -46.32% |
| 2024-12-31 | CN¥26.74 Billion ≈ $3.91 Billion |
CN¥4.49 Billion ≈ $657.45 Million |
0.168x | -27.54% |
| 2023-12-31 | CN¥23.02 Billion ≈ $3.37 Billion |
CN¥5.34 Billion ≈ $780.98 Million |
0.232x | +25.09% |
| 2022-12-31 | CN¥16.87 Billion ≈ $2.47 Billion |
CN¥3.13 Billion ≈ $457.65 Million |
0.185x | -8.00% |
| 2021-12-31 | CN¥14.13 Billion ≈ $2.07 Billion |
CN¥2.85 Billion ≈ $416.62 Million |
0.202x | +27.14% |
| 2020-12-31 | CN¥14.00 Billion ≈ $2.05 Billion |
CN¥2.22 Billion ≈ $324.77 Million |
0.158x | -0.58% |
| 2019-12-31 | CN¥13.91 Billion ≈ $2.03 Billion |
CN¥2.22 Billion ≈ $324.38 Million |
0.159x | -30.12% |
| 2018-12-31 | CN¥12.95 Billion ≈ $1.89 Billion |
CN¥2.95 Billion ≈ $432.19 Million |
0.228x | +127.17% |
| 2017-12-31 | CN¥11.98 Billion ≈ $1.75 Billion |
CN¥1.20 Billion ≈ $176.06 Million |
0.100x | -33.27% |
| 2016-12-31 | CN¥11.47 Billion ≈ $1.68 Billion |
CN¥1.73 Billion ≈ $252.48 Million |
0.150x | +35.54% |
| 2015-12-31 | CN¥11.16 Billion ≈ $1.63 Billion |
CN¥1.24 Billion ≈ $181.37 Million |
0.111x | -0.06% |
| 2014-12-31 | CN¥10.97 Billion ≈ $1.61 Billion |
CN¥1.22 Billion ≈ $178.34 Million |
0.111x | +6.02% |
| 2013-12-31 | CN¥10.02 Billion ≈ $1.47 Billion |
CN¥1.05 Billion ≈ $153.70 Million |
0.105x | +135.82% |
| 2012-12-31 | CN¥9.06 Billion ≈ $1.33 Billion |
CN¥402.77 Million ≈ $58.94 Million |
0.044x | +2.77% |
| 2011-12-31 | CN¥7.93 Billion ≈ $1.16 Billion |
CN¥342.93 Million ≈ $50.18 Million |
0.043x | +104.24% |
| 2010-12-31 | CN¥7.05 Billion ≈ $1.03 Billion |
CN¥149.29 Million ≈ $21.85 Million |
0.021x | -86.66% |
| 2009-12-31 | CN¥1.58 Billion ≈ $231.12 Million |
CN¥250.69 Million ≈ $36.68 Million |
0.159x | -14.55% |
| 2008-12-31 | CN¥1.19 Billion ≈ $174.17 Million |
CN¥221.08 Million ≈ $32.35 Million |
0.186x | -23.77% |
| 2007-12-31 | CN¥691.22 Million ≈ $101.15 Million |
CN¥168.42 Million ≈ $24.65 Million |
0.244x | -- |
About Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, ve… Read more